Patents by Inventor Ying Luo
Ying Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040161899Abstract: A metal oxide high-k dielectric is deposited on a semiconductor wafer in a manner that reduces dangling bonds in the dielectric without significantly thickening interfacial oxide thickness. A metal oxide precursor and radical oxygen and/or radical nitrogen are co-flowed over the semiconductor wafer to form the high-k dielectric. The radicals bond to dangling bonds of the metal of the metal oxide during the deposition process that is performed at the regular deposition temperature of less than about 400 degrees Celsius. The radical oxygen and radical nitrogen do not require the higher temperatures generally required in an anneal in order to attach to the dangling bonds of the metal. Thus, a high temperature post deposition anneal, which tends to cause interfacial oxide growth, is not required. The dielectric is of higher quality than is typical because the dangling bonds are removed during deposition rather than after the dielectric has been deposited.Type: ApplicationFiled: February 14, 2003Publication date: August 19, 2004Inventors: Tien Ying Luo, Ricardo Garcia, Hsing H. Tseng
-
Publication number: 20040115745Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract, hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or apart thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which has a label for imaging the tumor.Type: ApplicationFiled: November 5, 2003Publication date: June 17, 2004Inventors: Eleftherios P. Diamandis, Liu-Ying Luo
-
Patent number: 6737232Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: November 17, 1999Date of Patent: May 18, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Xiang Xu, Cindy Leo, Betty Huang, Mary Shen
-
Patent number: 6709839Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: September 24, 1999Date of Patent: March 23, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Helena Mancebo
-
Patent number: 6696263Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: September 23, 1999Date of Patent: February 24, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Betty Huang
-
Patent number: 6660511Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: March 3, 2000Date of Patent: December 9, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Xiang Xu
-
Publication number: 20030211546Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: ApplicationFiled: January 21, 2003Publication date: November 13, 2003Inventors: Ying Luo, Xiang Xu
-
Patent number: 6645766Abstract: The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5′ and 3′ ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.Type: GrantFiled: January 7, 2002Date of Patent: November 11, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Pei Wen Yu, James Lorens
-
Patent number: 6623980Abstract: The present invention is directed to novel exocytotic polypeptides, such as Exo1 and Exo2 polypeptides and related molecules, which have an inhibitory effect on exocytosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are method for identifying novel compositions which mediate exocytotic polypeptide bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: February 23, 1999Date of Patent: September 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Joseph Fisher, James Lorens, David Anderson, Ying Luo, Chao Bai (Betty) Huang, Mary Shen
-
Patent number: 6617102Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: October 25, 2000Date of Patent: September 9, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Eva Chan, Xiang Xu, Betty Huang, Valeria Ossovskaya
-
Patent number: 6589725Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: October 25, 1999Date of Patent: July 8, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Eva Chan, Xiang Xu, Betty Huang
-
Patent number: 6569658Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: August 24, 2000Date of Patent: May 27, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, C. Alan Fu, Mary Shen
-
Patent number: 6562591Abstract: The present invention is directed to polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: October 21, 1999Date of Patent: May 13, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, C. Alan Fu, Mary Shen
-
Publication number: 20030077597Abstract: The present invention provides compositions and methods for modulating cell proliferation, survival, morphology, and migration. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating proliferation, survival, morphology and migration in mammalian cells are provided. Compositions and methods for the treatment of disorders related to cell proliferation, survival, morphology and migration are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating proliferation, survival, morphology and migration in mammalian cells.Type: ApplicationFiled: October 19, 2001Publication date: April 24, 2003Inventors: Ying Luo, C. Alan Fu, Mary Shen
-
Publication number: 20030049651Abstract: Proteins that trigger immune responses in cancer patients are described. The proteins include protein phosphatase 4 regulatory subunit (Genbank AJ271448); a protein product corresponding to Genbank AK001674; putative translation initiation factor (SUI1) (Genbank NM-005801); RNA helicase (Genbank AL359945); MIL1 protein, nuclear gene encoding mitochondrial protein (NM-015367); MacMarks protein (Genbank X70326); chromosome 11 open reading frame 10 (c11orf10) (Genbank AF0867763); and, plakophilin 4 (PKP4) (Genbank NM-003628). In addition, a novel nucleic acid molecule identified in an immunoscreen of a breast carcinoma cDNA library is described. Diagnostic and therapeutic applications are also described.Type: ApplicationFiled: March 5, 2002Publication date: March 13, 2003Applicant: Mount Sinai HospitalInventors: Liu-Ying Luo, Eleftherios P. Diamandis
-
Publication number: 20030017601Abstract: The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5′ and 3′ ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.Type: ApplicationFiled: January 7, 2002Publication date: January 23, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Pei Wen Yu, James Lorens
-
Publication number: 20030013108Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: ApplicationFiled: June 7, 2002Publication date: January 16, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, PeiWen Yu, Mary Shen, Betty Huang
-
Patent number: 6428980Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: November 16, 1999Date of Patent: August 6, 2002Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, PeiWen Yu, Mary Shen, Betty Huang
-
Publication number: 20020081608Abstract: The invention relates to the identification of tumor associated proteins, novel nucleic acid molecules encoding tumor associated proteins and proteins encoded by such nucleic acid molecules; and uses of the tumor associated proteins.Type: ApplicationFiled: July 19, 2001Publication date: June 27, 2002Inventors: Liu-Ying Luo, Eleftherios P. Diamandis
-
Patent number: 6391582Abstract: The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5′ and 3′ ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.Type: GrantFiled: December 9, 1998Date of Patent: May 21, 2002Assignee: Rigel Pharmaceuticlas, Inc.Inventors: Ying Luo, Pei Wen Yu, James Lorens